Physician profile
Jesse H Yoon
NPI 1982198032
$12,504.46
in general payments reported to CMS, 2019-2025
30 companies · $4,045 in 2025
The $4,045 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $685 · 2022: $4,543 · 2023: $1,531 · 2024: $1,576 · 2025: $4,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,460 · Consulting Fee: $593 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,459.89 |
| Consulting Fee | $592.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,470.48 | 2022-2025 | Spevigo |
| Abbvie INC. | $1,298.07 | 2020-2025 | Rinvoq |
| Janssen Biotech, INC. | $1,270.76 | 2022-2025 | Tremfya, Stelara |
| Galderma Laboratories, L.P. | $752.46 | 2021-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $723.70 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $501.84 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $445.14 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $435.06 | 2022-2025 | Sotyktu |
| Incyte Corporation | $403.58 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $374.77 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $312.01 | 2021-2023 | Siliq |
| Pfizer INC. | $308.71 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $305.25 | 2021-2023 | Tremfya |
| Genentech USA, INC. | $281.74 | 2021-2022 | |
| Lilly USA, LLC | $247.91 | 2024-2025 | Taltz, Ebglyss |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $217.15 | 2025 | Bimzelx |
| Leo Pharma INC. | $200.37 | 2024-2025 | Adbry, Anzupgo |
| Cipher Pharmaceuticals US LLC | $196.37 | 2025 | Natroba, Spinosad |
| Amgen INC. | $142.95 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $131.98 | 2024-2025 | |
| Biofrontera INC. | $125.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $97.92 | 2022-2025 | |
| Epi Health, LLC | $70.00 | 2022 | |
| Journey Medical Corporation | $59.23 | 2025 | |
| Mayne Pharma Commercial LLC | $45.76 | 2025 | |
| Strata Skin Sciences, INC. | $18.76 | 2025 | Xtrac |
| Merck Sharp & Dohme LLC | $17.67 | 2021 | |
| Organon LLC | $17.59 | 2025 | |
| Fidia Pharma USA INC. | $17.33 | 2024 | |
| Botanix Sb INC | $14.90 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.